



Company Contact - Jim Dorsey  
**BioClinica**  
267-757-3040

Media Contact – Brian Gawron  
**Diccicco Battista Communications**  
215-957-0300

Investor Contact - Linda Decker  
Investor Media – Bill Gordon  
**Porter, LeVay & Rose, Inc.**  
212-564-4700

---

**FOR IMMEDIATE RELEASE**

### **BIOCLINICA'S EXPRESS PLATFORM RECEIVES CDISC CERTIFICATION**

**SAN DIEGO, CA, June 22, 2009** – Bio-Imaging Technologies, Inc., (NASDAQ: BITI) d/b/a BioClinica, a leading global provider of clinical trial services, today announced that its Express EDC platform has been certified by the Clinical Data Interchange Standard Consortium (CDISC) as complying with the Operational Data Model (ODM) standard.

The leading choice for challenging clinical trial environments, BioClinica Express is designed to help sponsors keep investigators happy, monitor protocol compliance and close studies faster, while still meeting all regulations and guidelines. It is a comprehensive EDC solution that uses stable technology to provide a central hub to coordinate and organize the collection and dissemination of clean data, adding speed and quality to every part of the clinical trial process.

BioClinica Express Platform is now certified on four export use-cases, including:

- ODM Data Export, Snapshot, Metadata
- ODM Data Export, Snapshot, Data
- ODM Data Export, Transactional, Metadata
- ODM Data Export, Transactional, Data

“It is great that another vendor has swelled the ranks of those who are ODM certified, especially as BioClinica’s certification went very smoothly,” said Dave Iberson-Hurst, Vice President of Technical Strategy at CDISC. “CDISC appreciates the support for the CDISC ODM standard made by BioClinica in adding this feature to their toolset.”

CDISC is a global, industry-supported non-profit organization that establishes standards to support the acquisition, exchange, submission and archive of clinical research data and metadata. The CDISC mission is to develop and support global, platform-independent data standards that enable information system interoperability to improve medical research and related areas of healthcare. The Operational Data Model (ODM) provides a format for representing the study of metadata, study data and administrative data associated with a clinical trial. It represents only the data that would be transferred among different software systems during a trial, or archived after a trial.

-more-

## **About BioClinica**

Bio-Imaging Technologies, Inc. d/b/a BioClinica is a leading global provider of clinical trials services, helping to support drug and product development efforts through all phases of the clinical trial process. Created from the acquisition of Phoenix Data Systems, Inc. by Bio-Imaging Technologies, Inc., BioClinica offers industry-leading medical image management and best-of-breed electronic data capture to companies in the life sciences industry. In addition, BioClinica offers solutions that combine these core services to maximize efficiency and manageability throughout the entire clinical development process. With more than 2,000 successful trials, BioClinica is unsurpassed in its knowledge and experience, helping bring many of today's drugs from early phase development through final approval. BioClinica operates two state-of-the-art, FDA-compliant core labs in the United States and Europe, with business offices in the United States, France, Germany, United Kingdom and the Netherlands. For more information, please visit [www.bioclinica.com](http://www.bioclinica.com).

*Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.*

#####